Sintilimab plus lenvatinib in combination with transarterial chemoembolization and subsequent radiofrequency ablation for unresectable hepatocellular carcinoma: a single-arm, single-center study

Sintilimab plus lenvatinib in combination with transarterial chemoembolization and subsequent radiofrequency ablation for unresectable hepatocellular carcinoma: a single-arm, single-center study

Abstract This study was designed to assess the safety and efficacy of Sintilimab plus Lenvatinib in combination with transarterial chemoembolization (TACE) and subsequent radiofrequency ablation (RFA) in the treatment of unresectable hepatocellular carcinoma (HCC). A retrospective data analysis was...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaochun Chen, Changping Wang, Yuanjie Tang, Haoyan Sun, Hongling Liu, Chuan Lin, Zhiping Yuan
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
TACE
RFA
PD-1 inhibitors
TKIs
Liver cancer
Online Access:https://doi.org/10.1038/s41598-025-12858-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-12858-y

Similar Items